 Sense Proteomic works with The Sage Group to develop global strategic alliances in novel biomarkers for oncology and autoimmune disease
Date: 19 Apr 2010
Oxford UK – 19th April 2010 – Sense Proteomic Ltd. has announced the appointment of The Sage Group as its business development consultant to assist in expanding its global biomarker discovery partnerships. Sense is part of Oxford Gene Technology (OGT), the pioneer of microarray-based technologies, founded by Professor Ed Southern of Oxford University in the UK.
Sage is a global firm focused on healthcare and life science transactions, with offices in the USA, Europe, Japan, Australia and Israel.
Sense has developed a novel ‘functional protein’ microarray technology from which it is identifying biomarkers associated with the early onset of prostate and colorectal cancer. The technology platform offers a number of competitive and technical advantages for high throughput biomarker discovery and Sense is seeking partners who wish to use Sense’s skills and experience for their own biomarker identification and validation studies.
Sense will be attending the BIO meeting in Chicago from 3-6 May 2010. It will be meeting potential partners during this key meeting.
Building on its two external collaborations and its internal discovery programs, Sense is partnering with companies to exploit the power of its novel biomarker discovery and validation platform. Sense’s focus is on novel biomarkers for oncology and autoimmune disease, and it holds exciting and revolutionary IP in this space, which can achieve a more specific and sensitive range of diagnostic tests. This, together with its strong clinical network, allows unparalleled access to enable rapid development of new products.
Rachel Fallon of Sense Proteomic said, “We are very pleased to work with The Sage Group; their strong healthcare and life science industry network will bring a new dimension to the unique biomarker development and validation program we provide to our clients, and will assist in the value creation process that Sense Proteomic seeks to develop.”
Bill Mason of The Sage Group said, “We are delighted to work with Sense Proteomic, with whom we have collaborated in the past. Their technology will be of interest to a wide range of diagnostics and pharmaceutical companies, with whom we are developing strategic alliances throughout 2010.”
About The Sage Group, Inc. (WWW.SAGEHEALTHCARE.COM)
The Sage Group Inc. is a leader in the provision of strategic and transactional advice to health care companies in the pharmaceutical, diagnostics, medical device, biotechnology and life science fields. Sage currently maintains offices in Clinton, NJ; Cambridge, England; and Yokohama, Japan. Since its founding in 1994, The Sage Group has served more than 200 clients in the US, Europe and Asia, and completed numerous transactions including divestitures, alliances, acquisitions and financings with values ranging from $5 million to $500 million. The establishment of operations in Europe and Japan and more recently Australia allows its clients to reach out beyond their own regions and capture the potential of the global healthcare market.
The Sage Group is an organization of experienced and successful executives who are committed to the service of the very vital and dynamic health care industry and its investors.
About Sense Proteomic Limited (www.senseproteomic.com)
Sense Proteomic Limited, part of Oxford Gene Technology (OGT), is a biomarker discovery company utilising its proprietary protein array technology to discover and commercialise autoantibody biomarkers for cancer and autoimmune diseases.
OGT, founded by Professor Ed Southern, has a proven pedigree in microarray technology and services. Their mission is to advance molecular medicine through the provision of innovative clinical genetics and diagnostics solutions.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park,
Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.co.uk
W: www.ogt.co.uk
|